Publications

A selection of recent and significant publications can be viewed below.

Membranous nephropathy: Pilot study of a novel regimen combining cyclosporine and Rituximab.

Waldman M, Beck LH Jr, Braun M, Wilkins K, Balow JE, Austin HA 3rd.

Kidney Int Rep (2016 Jul) 1:73-84. Abstract/Full Text

A Clinical Service to Support the Return of Secondary Genomic Findings in Human Research.

Darnell AJ, Austin H, Bluemke DA, Cannon RO 3rd, Fischbeck K, Gahl W, Goldman D, Grady C, Greene MH, Holland SM, Hull SC, Porter FD, Resnik D, Rubinstein WS, Biesecker LG.

Am J Hum Genet (2016 Mar 3) 98:435-441. Abstract/Full Text

miR-150 promotes renal fibrosis in lupus nephritis by downregulating SOCS1.

Zhou H, Hasni SA, Perez P, Tandon M, Jang SI, Zheng C, Kopp JB, Austin H 3rd, Balow JE, Alevizos I, Illei GG.

J Am Soc Nephrol (2013 Jun) 24:1073-87. Abstract/Full Text

Treatment of idiopathic membranous nephropathy.

Waldman M, Austin HA 3rd.

J Am Soc Nephrol (2012 Oct) 23:1617-30. Abstract/Full Text

The rising incidence of intentional ingestion of ethanol-containing hand sanitizers.

Gormley NJ, Bronstein AC, Rasimas JJ, Pao M, Wratney AT, Sun J, Austin HA, Suffredini AF.

Crit Care Med (2012 Jan) 40:290-4. Abstract/Full Text

Controversies in the treatment of idiopathic membranous nephropathy.

Waldman M, Austin HA 3rd.

Nat Rev Nephrol (2009 Aug) 5:469-79. Abstract/Full Text

Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy.

Austin HA 3rd, Illei GG, Braun MJ, Balow JE.

J Am Soc Nephrol (2009 Apr) 20:901-11. Abstract/Full Text

Urinary exosomal transcription factors, a new class of biomarkers for renal disease.

Zhou H, Cheruvanky A, Hu X, Matsumoto T, Hiramatsu N, Cho ME, Berger A, Leelahavanichkul A, Doi K, Chawla LS, Illei GG, Kopp JB, Balow JE, Austin HA 3rd, Yuen PS, Star RA.

Kidney Int (2008 Sep) 74:613-21. Abstract/Full Text

Long-term effects of combination treatment with fludarabine and low-dose pulse cyclophosphamide in patients with lupus nephritis.

Illei GG, Yarboro CH, Kuroiwa T, Schlimgen R, Austin HA, Tisdale JF, Chitkara P, Fleisher T, Klippel JH, Balow JE, Boumpas DT.

Rheumatology (Oxford) (2007 Jun) 46:952-6. Abstract/Full Text

Nephrotic syndrome: an under-recognised immune-mediated complication of non-myeloablative allogeneic haematopoietic cell transplantation.

Srinivasan R, Balow JE, Sabnis S, Lundqvist A, Igarashi T, Takahashi Y, Austin H, Tisdale J, Barrett J, Geller N, Childs R.

Br J Haematol (2005 Oct) 131:74-9. Abstract/Full Text

Membranous lupus nephritis.

Austin HA, Illei GG.

Lupus (2005) 14:65-71. Abstract/Full Text

Parapelvic kidney cysts: a distinguishing feature with high prevalence in Fabry disease.

Ries M, Bettis KE, Choyke P, Kopp JB, Austin HA 3rd, Brady RO, Schiffmann R.

Kidney Int (2004 Sep) 66:978-82. Abstract/Full Text

Maintenance therapy for lupus nephritis--something old, something new.

Balow JE, Austin HA 3rd.

N Engl J Med (2004 Mar 4) 350:1044-6. Abstract/Full Text

Treatment of proliferative lupus nephritis.

Balow JE, Austin HA 3rd.

Am J Kidney Dis (2004 Feb) 43:383-5. Abstract/Full Text

Clinical usefulness of a functional assay for the von Willebrand factor cleaving protease (ADAMTS 13) and its inhibitor in a patient with thrombotic thrombocytopenic purpura.

Rick ME, Austin H, Leitman SF, Krizek DM, Aronson DL.

Am J Hematol (2004 Feb) 75:96-100. Abstract/Full Text

Therapy of membranous nephropathy in systemic lupus erythematosus.

Balow JE, Austin HA 3rd.

Semin Nephrol (2003 Jul) 23:386-91. Abstract/Full Text

Impaired renal function in progressive multiple sclerosis.

Calabresi PA, Austin H, Racke MK, Goodman A, Choyke P, Maloni H, McFarland HF.

Neurology (2002 Dec 10) 59:1799-801. Abstract/Full Text

Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies.

Illei GG, Takada K, Parkin D, Austin HA, Crane M, Yarboro CH, Vaughan EM, Kuroiwa T, Danning CL, Pando J, Steinberg AD, Gourley MF, Klippel JH, Balow JE, Boumpas DT.

Arthritis Rheum (2002 Apr) 46:995-1002. Abstract/Full Text

Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis.

Illei GG, Austin HA, Crane M, Collins L, Gourley MF, Yarboro CH, Vaughan EM, Kuroiwa T, Danning CL, Steinberg AD, Klippel JH, Balow JE, Boumpas DT.

Ann Intern Med (2001 Aug 21) 135:248-57. Abstract/Full Text

Enzyme replacement therapy in Fabry disease: a randomized controlled trial.

Schiffmann R, Kopp JB, Austin HA 3rd, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO.

JAMA (2001 Jun 6) 285:2743-9. Abstract/Full Text

Treatment of lupus nephritis.

Austin HA, Balow JE.

Semin Nephrol (2000 May) 20:265-76. Abstract/Full Text

Progress in the treatment of proliferative lupus nephritis.

Balow JE, Austin HA 3rd.

Curr Opin Nephrol Hypertens (2000 Mar) 9:107-15. Abstract/Full Text

New prospects for treatment of lupus nephritis.

Balow JE, Boumpas DT, Austin HA 3rd.

Semin Nephrol (2000 Jan) 20:32-9. Abstract/Full Text

A pilot study of low-dose fludarabine in membranous nephropathy refractory to therapy.

Boumpas DT, Tassiulas IO, Fleisher TA, Vaughan E, Piscitelli S, Kim Y, Pucino F, Balow JE, Austin HA.

Clin Nephrol (1999 Aug) 52:67-75. Abstract/Full Text

Natural history and treatment of lupus nephritis.

Austin HA, Balow JE.

Semin Nephrol (1999 Jan) 19:2-11. Abstract/Full Text